Cash, cash equivalents and marketable securities were $352M as of December 31, 2022. "In 2022, we made significant progress advancing our LYNX, CANYON, ARCH and DUNE clinical trials, notably with the 6-month data from the ARCH open label study in individuals with BMD, which reinforces our confidence behind EDG-5506. Moreover, our discovery platform continues to yield differentiated precision medicines, exemplified by EDG-7500, a novel sarcomere modulator for HCM which has entered IND-enabling studies," said Kevin Koch, president and CEO of Edgewise. "In 2023, we see continued momentum for our growing pipeline, including a planned 12-month BMD readout from our ARCH open label study, interim DMD data from our Phase 2 LYNX trial, a potentially registration-enabling cohort in CANYON and a Phase 1 trial for EDG-7500 in HCM."
Published first on TheFly